Contact
Subscribe

Category

2026

[article_filters]
Website_maat_logo

,

Key Results from the CHRONOS Multicentre Retrospective Cohort Study Describing Patient Outcomes in Third-Line Acute Gastrointestinal GvHD

MaaT Pharma
February 26, 2026
Website_maat_logo

,

THRASSA, A Multicenter, Open-label Study Evaluating The Safety, Tolerability And Efficacy Of MaaT013 In Ruxolitinib-refractory Or Intolerant Paediatric/ Adolescent Participants With Gastrointestinal Acute Graft-versus-Host Disease

MaaT Pharma
February 26, 2026
Website_maat_logo

,

MaaT033 For Gut Microbiota Optimization To Improve Survival After Allogenic HCT: The PHOEBUS Trial

MaaT Pharma
February 26, 2026
cropped-Website_maat_logo.png

February 3, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma
February 3, 2026
Website_maat_logo

January 20, 2026: MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

MaaT Pharma
January 20, 2026

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

MaaT Pharma in the News